Displaying 1 - 12 of 30
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Cirrhosis & Complications
4

Shionogi:  Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View